Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study

BACKGROUND: In randomised clinical trials, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium–glucose cotransporter 2 (SGLT-2) inhibitors reduced cardiovascular events in patients with type 2 diabetes (T2D) at high cardiovascular risk, as compared to standard care. However, data compar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cardiovasc Diabetol
Hauptverfasser: Thein, David, Christiansen, Mia Nielsen, Mogensen, Ulrik Madvig, Bundgaard, Johan Skov, Rørth, Rasmus, Madelaire, Christian, Fosbøl, Emil Loldrup, Schou, Morten, Torp-Pedersen, Christian, Gislason, Gunnar, Køber, Lars, Kristensen, Søren Lund
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2020
Schlagworte:
Original Investigation
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7339487/
https://ncbi.nlm.nih.gov/pubmed/32631337
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01078-5
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge